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CORRESPONDENCE
Letters to the Editor
Implantable Cardioverter-
Defibrillator Shocks and Their
Adverse Impact on Patient-Centered
Outcomes: Fact or Fiction?
In a recent issue of the Journal, Daubert et al. (1) reported the
impact of inappropriate implantable cardioverter-defibrillator
(ICD) shocks on health outcomes in the MADIT II (Multicenter
Automatic Defibrillator Trial II). The incidence of 1 or more
inappropriate shocks was 11.5%, inappropriate shocks comprised
31.2% of all shock episodes, and inappropriate shocks predicted a
2-fold increased mortality risk. In their conclusions, the authors
refer to the potential detrimental effects of inappropriate shocks on
quality of life but also state that this association is not yet
established. In an accompanying editorial, Dr. Raitt (2) also refers
to the effect of shocks on patient-centered outcomes such as quality
of life and psychological distress.
However, the majority of references cited to substantiate this
impact of shocks on patient-centered outcomes were published
more than a decade ago (3– 6). What is more, neither Daubert
et al. (1) nor Raitt (2) cite any studies that failed to find a
relationship between shocks and patient-centered outcomes, al-
though these data are available (7–12). Differences in study design
and the way that shocks were assessed (e.g., self-report vs.
objectively measured) and quantified (e.g., shocks/no shocks vs.
number of shocks) may in part explain these mixed findings. For
example, in the Canadian Implantable Defibrillator Study there
was a dose-response relationship, with only patients experiencing
5 shocks being at risk for impaired quality of life (13).
Alternatively, the inconsistency in findings may be attributed to
whether factors that may potentially compete with shocks as a
determinant of outcome were accounted for. Sears et al. (14)
showed that although shocks had a significant effect on quality of
life, this effect was relatively small compared with that of psycho-
logical factors such as optimism, trait-anxiety, history of depres-
sion, and social support. We showed that device-related concerns
and Type D personality (i.e., tendency to experience negative
emotions and to inhibit self-expression) had a greater effect on
anxiety and depression after ICD implantation compared with
shocks (15). In another study, we found that anxiety and depres-
sion levels were higher in nonshocked Type D patients than in
shocked non–Type D patients, indicating that personality factors
may play a substantial role in this context (9).
Taken together, it seems fair to conclude that research on
shocks and patient-centered outcomes has produced inconsistent
findings and that other factors may be equally (or even more)
important in predicting these outcomes after ICD implantation.
With changes in ICD programming and the use of new antitachy-
cardia pacing therapies (16) leading to a reduction in shocks and
better quality of life (17), it may be time for a paradigm shift that
includes looking at the role of other factors in addition to shocks.
The ICD shocks may indeed be a “double-edged sword” in terms
of their adverse impact on prognosis (2), but their impact on
patient-centered outcomes may be more benign than generally
assumed. From a clinical perspective, this observation does not
imply that shocks are not important in terms of patient-centered
outcomes, but rather that the ICD patient’s psychological profile is
of major importance.
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Reply
We thank Dr. Pedersen and Ms. van den Broek for their inter-
est regarding our recent article (1) and for drawing attention to
the potential quality-of-life issues associated with implantable
cardioverter-defibrillator (ICD) shocks. The authors emphasize that
the relationship between ICD shocks, appropriate or inappropriate,
and health-related quality of life is neither simple nor linear. For
example, some studies have not found an effect of shocks on quality of
life. Other studies either have (2) or have not (3) found an effect
between number of shocks and adverse psychologic effect. Similarly,
patients with multiple appropriate shocks, for example, ventricular
arrhythmia storm, appear to be at particularly high risk for subsequent,
largely nonsudden, death in follow-up (4). Patient-related factors such
as age or personality type likely do play a role in the magnitude of
effect a shock has on the patient (1,5,6). In MADIT II (Multicenter
Automatic Defibrillator Trial II), while personality subtypes, such as
type D (7), were not specifically inventoried or analyzed ( 8), mental
health was not observed to change in patients completing follow-up
quality-of-life questionnaires, although declines in physical health
were noted for patients experiencing appropriate shocks, likely due to
worsening congestive heart failure (9). In summary, further work is
needed to reduce the occurrence of ICD shocks, both appropriate and
inappropriate, while maintaining the mortality reduction with ICDs,
and to anticipate, understand, and mitigate the effects of the shocks
when they cannot be prevented.
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Initial Assessment of
Clinical Impact of a Drug
Interaction Between Clopidogrel
and Proton Pump Inhibitors
After reading the article by Gilard et al. (1) regarding the influence of
omeprazole on the antiplatelet action of clopidogrel associated with
aspirin, we examined our medical and pharmacy databases for acute
myocardial infarction (MI) rates in members receiving clopidogrel
with or without concurrent proton pump inhibitor (PPI) therapy.
Our analysis included members younger than age 65 years who
were determined to be adherent to clopidogrel therapy. Members
were assigned to a no PPI exposure group (control), low PPI exposure
group, or high PPI exposure group based on adherence rates to PPIs.
Members were studied for a period of 1 year for claims with
International Classification of Diseases-9th Revision diagnoses indic-
ative of MI after starting clopidogrel therapy. We also examined
comorbidities and severity of illness at the time of first clopidogrel use.
Our findings revealed 1-year acute MI rates of 1.38% (66 of
4,800 patients) in the control group, 3.08% (22 of 712 patients) in
the low PPI exposure group, and 5.03% in the high PPI exposure
group. Using the control group MI incidence as the expected MI
rate, the difference in MI rates between the control and high
exposure groups was significant (p  0.05). Subsequent analysis
identified small but significant comorbidity differences between the
groups that could account for the findings. The high PPI exposure
group had a slightly greater number of individuals with pre-
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